AIPT Precision Therapeutics

Predictive Oncology CEO Letter to Shareholders

Predictive Oncology CEO Letter to Shareholders
EN
06/10/2020

Underlying

AIPTPrecision Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precision Therapeutics

 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Develops Functional 3D Organoid Models Exclusively...

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing agreement, Predictive Oncology rec...

June 12, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Court Denies Renovaro Motion for an Expedited Trial in July

Court Denies Renovaro Motion for an Expedited Trial in July PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premis...

May 27, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Reg...

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to aggressively pursue novel drug discovery, biomarker discovery and drug repurposing using AI and machine learning. Earlier this week, Regeneron Pharmaceuticals annou...

May 22, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolution...

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health" Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in 2024 and projected to grow at a 19.4% CAGR through 2030, Predictive Oncology is poised to lead in precision oncology innovation PITTSBURGH, May 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery...

May 20, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Reports First Quarter 2025 Financial Results and P...

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of ap...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch